Delving into the Latest Updates on Miglitol with Synapse

The aim of this study was to investigate the hypoglycemic effects of 25 mg, 50 mg, and 75 mg of Miglitol (trade name: SEIBULE®) produced by Sanwa Chemical Research Institute Co., Ltd. in healthy subjects, to determine the dosage for the formal human bioequivalence trial, and to investigate the safety of Miglitol (SEIBULE®) in healthy subjects.

Start Date02 Apr 2024

Sponsor / Collaborator

Ningbo Menovo TianKang Pharmaceutical Co., Ltd.

ChiCTR2300074474 / RecruitingEarly Phase 1IIT

A single arm multicenter clinical study of miglitol in the treatment of muscle invasive bladder cancer

Start Date17 Mar 2023

Sponsor / Collaborator-

100 Clinical Results associated with Miglitol

Login to view more data

100 Translational Medicine associated with Miglitol

Login to view more data

100 Patents (Medical) associated with Miglitol

Login to view more data

362

Literatures (Medical) associated with Miglitol

31 Dec 2024·Journal of Enzyme Inhibition and Medicinal Chemistry

New natural protein tyrosine phosphatase 1B inhibitors from Gynostemma pentaphyllum

Article

Author: Tan, Daopeng ; Du, Yimei ; Zhang, Qianru ; Wu, Di ; Wu, Xingdong ; Xie, Jian ; Wang, Xianting ; Deng, Yidan ; He, Yuqi ; Wang, Jianmei ; Qin, Lin

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease mainly caused by insulin resistance, which can lead to a series of complications such as cardiovascular disease, retinopathy, and its typical clinical symptom is hyperglycaemia. Glucosidase inhibitors, including Acarbose, Miglitol, are commonly used in the clinical treatment of hypoglycaemia. In addition, Protein tyrosine phosphatase 1B (PTP1B) is also an important promising target for the treatment of T2DM. Gynostemma pentaphyllum is a well-known oriental traditional medicinal herbal plant, and has many beneficial effects on glucose and lipid metabolism. In the present study, three new and nine known dammarane triterpenoids isolated from G. pentaphyllum, and their structures were elucidated by spectroscopic methods including HR-ESI-MS,¹H and ¹³C NMR and X-ray crystallography. All these compounds were evaluated for inhibitory activity against α-glucosidase, α-amylase and PTP1B. The results suggested that compounds 7∼10 were potential antidiabetic agents with significantly inhibition activity against PTP1B in a dose-dependent manner.

31 Dec 2024·Journal of Enzyme Inhibition and Medicinal Chemistry

Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies

Article

Author: Jankovic, Aleksandar ; Djurkovic, Filip ; Zlatovic, Mario ; Sladic, Dusan ; Vulovic, Bojan ; Prodanovic, Radivoje ; Saicic, Radomir N. ; Vallet, Thomas ; Ferjancic, Zorana ; Trmcic, Milena ; Vignuzzi, Marco ; Bihelovic, Filip ; Pavlovic, Milos ; Kalicanin, Nevena ; Matovic, Radomir ; Djurdjevic Djelmas, Aleksandra

We developed new iminosugar-based glycosidase inhibitors against SARS-CoV-2. Known drugs (miglustat, migalastat, miglitol, and swainsonine) were chosen as lead compounds to develop three classes of glycosidase inhibitors (α-glucosidase, α-galactosidase, and mannosidase). Molecular modelling of the lead compounds, synthesis of the compounds with the highest docking scores, enzyme inhibition tests, and in vitro antiviral assays afforded rationally designed inhibitors. Two highly active α-glucosidase inhibitors were discovered, where one of them is the most potent iminosugar-based anti-SARS-CoV-2 agent to date (EC₉₀ = 1.94 µM in A549-ACE2 cells against Omicron BA.1 strain). However, galactosidase inhibitors did not exhibit antiviral activity, whereas mannosidase inhibitors were both active and cytotoxic. As our iminosugar-based drug candidates act by a host-directed mechanism, they should be more resilient to drug resistance. Moreover, this strategy could be extended to identify potential drug candidates for other viral infections.

15 Oct 2024·Internal Medicine

Severe Acute Interstitial Nephritis Induced by α-glucosidase Inhibitor Miglitol in an Elderly Patient with Type 2 Diabetic Nephropathy

Article

Author: Yoshizawa, Hiromichi ; Masuda, Takahiro ; Hishida, Erika ; Akimoto, Tetsu ; Nagata, Daisuke ; Imai, Toshimi ; Ono, Kazutoshi ; Satonaka, Hiroshi ; Ono, Yuko

A 79-year-old male patient with type 2 diabetic nephropathy and hypertension was admitted to our hospital because of acute kidney injury with significantly elevated serum creatinine (8.12 mg/dL) and urinary β2-microglobulin (β2MG, 31,748 μg/L) levels. α-glucosidase inhibitor (α-GI) miglitol, started two weeks prior to presentation, was discontinued because drug-induced acute interstitial nephritis (AIN) was suspected. Renal biopsy revealed AIN and diabetic nephropathy. The drug-induced lymphocyte stimulation test for miglitol was also positive. After the discontinuation of miglitol, the urinary β2MG levels decreased to the normal range. This case raises the possibility that α-GI miglitol can worsen the renal function in patients with underlying renal dysfunction.

100 Deals associated with Miglitol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00625	Miglitol	A10BF02	DB00491

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	11 Oct 2005
Diabetes Mellitus, Type 2	NL	-	23 Jul 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	US	Pfizer Inc.	-
Diabetes Mellitus, Noninsulin-Dependent, 2	Phase 1	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	07 Jun 2006
Diabetes Mellitus, Type 1	Phase 1	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	21 Sep 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2020	Not Applicable	-	-	Portal vein miglitol infusion upstream	velksnomcx(zbjuwypzmj) = snwmtnccng bhvtilgdea (yewworirvn ) View more	-	01 Jun 2020
				Portal vein miglitol infusion liver adjacent	velksnomcx(zbjuwypzmj) = anikmsvfdr bhvtilgdea (yewworirvn ) View more
JPRN-UMIN000006098 (EASD2013)	Not Applicable	Overweight	41	Miglitol	hlwqrsozyb(medyfjrnzt) = aphactyrgx crwtwdnlkc (ejquigcdcf, 0.11) View more	Positive	24 Sep 2013
				Sitagliptin	hlwqrsozyb(medyfjrnzt) = utinbwkqux crwtwdnlkc (ejquigcdcf, 0.17) View more